Another China Player To Watch? Sinocare Targets US Diabetes Market With Nipro Diagnostics
Sinocare Group, a Chinese specialist in biosensor-based blood glucose monitoring devices, is expanding into the US market after agreeing to buy Nipro Corporation’s diabetes business, Nipro Diagnostics. Sinocare gains US manufacturing sites and a ready-made US sales team in the deal, and the move could mark an important turning point in the company's internationalization strategy.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.